In the central nervous system, the primary targets of the human immunodefic
iency virus-1 (HIV-1) are microglia, resulting in a disorder called HIV-1 d
ementia. P-glycoprotein (P-gp), a membrane-associated ATP-dependent efflux
transporter, limits entry into the brain of numerous xenobiotics, including
anti-HIV drugs (i.e., protease inhibitors). This project investigates the
functional expression of P-gp in the endogenous immune cells of the brain,
a parenchymal compartment not previously studied. We used a cell line (MLS-
9) derived from rat microglia to study the transport of digoxin, a known P-
gp substrate. Reverse transcriptase-polymerase chain reaction analysis dete
cted mRNA for only mdr1b in IMLS-9 cells, whereas both mdr1a and mdr1b mRNA
were expressed in primary cultured microglia from which they were derived.
Western blot analysis with the C219 antibody detected a single band at sim
ilar to 170 to 180 kDa in MLS-9 cells, which is the size previously reporte
d for P-gp. Immunocytochemical analysis with the monoclonal antibodies C219
, MRK16, and MAB-448 labeled P-gp protein along the plasma membrane and nuc
lear envelope of MLS-9 cells. [H-3]Digoxin accumulation by monolayers of ML
S-9 cells was significantly enhanced in the presence of any of several P-gp
inhibitors (verapamil, cyclosporin A, quinidine, PSC 833), protease inhibi
tors (i.e., saquinavir, indinavir, and ritonavir), and sodium azide, an ATP
ase inhibitor. These results provide the first evidence for the functional
expression of P-gp in microglia and imply that entry of pharmacological age
nts, including protease inhibitors, may be prevented within the brain paren
chyma, as well as at the blood-brain barrier.